Google commits to support startups from seed to scale

IMT News Desk
IMT News Desk
· 2 min read

Launches Google Market Access Program to help startups overcome challenges in accessing global markets

Google reaffirmed its commitment to supporting India’s startup ecosystem at all stages of the AI lifecycle anchored in pillars across Infrastructure, Models, Datasets, and Programs to support Indian founders.

Highlighting the current challenge for India’s mature and fast-growing startup ecosystem, Google announced the Google Market Access Program, a first-of-its-kind initiative to help Indian startups strengthen their go-to-market efforts, shortening the journey from local pilots to global scale.

Google also announced new additions to its Gemma open model family, designed to help startups build population-scale and production-ready AI applications.

● MedGemma 1.5 addresses the growing demand for advanced healthcare AI, enabling startups to work with high-dimensional medical imaging at scale.

● FunctionGemma, a lightweight model optimized for function calling, supports the next generation of on-device, agent-based systems, allowing AI applications to take secure, reliable action locally. Together, these models expand the building blocks available to developers creating real-world, deployable solutions.

Preeti Lobana, Country Manager for India, Google, said, “Indian startups are building serious deep technology and solving population-scale problems with AI. Google’s focus is to support them across the full stack, from skills and infrastructure to trust and market access. While the path from labs to prototypes has become quite robust over the last several years, the scaling journey continues to be where a lot of startups struggle – The Google Market Access Program is designed to address this challenge faced by founders.”

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk